Lycia Therapeutics (NASDAQ:LYCA) Major Shareholder Buys $1,371,649.49 in Stock

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par bought 52,939 shares of Lycia Therapeutics stock in a transaction on Friday, October 23rd. The stock was purchased at an average price of $25.91 per share, for a total transaction of $1,371,649.49. Following the completion of the acquisition, the insider owned 52,939 shares in the company, valued at $1,371,649.49. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Tuesday, October 27th, Venrock Healthcare Capital Par purchased 39,796 shares of Lycia Therapeutics stock. The shares were purchased at an average cost of $26.62 per share, for a total transaction of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par purchased 1,952,705 shares of Lycia Therapeutics stock. The shares were purchased at an average price of $18.04 per share, with a total value of $35,226,798.20.

Lycia Therapeutics Price Performance

NASDAQ:LYCA opened at $27.73 on Friday. Lycia Therapeutics, Inc. has a 1-year low of $22.19 and a 1-year high of $36.49.

Lycia Therapeutics Company Profile

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.